Development of a new vaccine for the prevention of Lassa fever

Thomas Geisbert, Steven Jones, Elizabeth A. Fritz, Amy C. Shurtleff, Joan B. Geisbert, Ryan Liebscher, Allen Grolla, Ute Ströher, Lisa Fernando, Kathleen M. Daddario, Mary C. Guttieri, Bianca R. Mothé, Tom Larsen, Lisa E. Hensley, Peter B. Jahrling, Heinz Feldmann

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Background: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. Methods and Findings: We developed a replication-competent vaccine against Lassa virus based on attenuated recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single intramuscular vaccination of the Lassa vaccine elicited a protective immune response in nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected in the monkeys, and none of the animals developed fever or other symptoms of illness associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical disease. In contrast, the two control animals developed severe symptoms including rashes, facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection. Conclusion: Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease.

Original languageEnglish (US)
Pages (from-to)537-545
Number of pages9
JournalPLoS Medicine
Volume2
Issue number6
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Lassa Fever
Vaccines
Lassa virus
Vesicular Stomatitis
Viruses
Primates
Haplorhini
Vaccination
Viremia
Humoral Immunity
Exanthema
Cellular Immunity
Netherlands
Germany
Edema
Glycoproteins
Fever
Animal Models
Public Health
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Geisbert, T., Jones, S., Fritz, E. A., Shurtleff, A. C., Geisbert, J. B., Liebscher, R., ... Feldmann, H. (2005). Development of a new vaccine for the prevention of Lassa fever. PLoS Medicine, 2(6), 537-545. https://doi.org/10.1371/journal.pmed.0020183

Development of a new vaccine for the prevention of Lassa fever. / Geisbert, Thomas; Jones, Steven; Fritz, Elizabeth A.; Shurtleff, Amy C.; Geisbert, Joan B.; Liebscher, Ryan; Grolla, Allen; Ströher, Ute; Fernando, Lisa; Daddario, Kathleen M.; Guttieri, Mary C.; Mothé, Bianca R.; Larsen, Tom; Hensley, Lisa E.; Jahrling, Peter B.; Feldmann, Heinz.

In: PLoS Medicine, Vol. 2, No. 6, 2005, p. 537-545.

Research output: Contribution to journalArticle

Geisbert, T, Jones, S, Fritz, EA, Shurtleff, AC, Geisbert, JB, Liebscher, R, Grolla, A, Ströher, U, Fernando, L, Daddario, KM, Guttieri, MC, Mothé, BR, Larsen, T, Hensley, LE, Jahrling, PB & Feldmann, H 2005, 'Development of a new vaccine for the prevention of Lassa fever', PLoS Medicine, vol. 2, no. 6, pp. 537-545. https://doi.org/10.1371/journal.pmed.0020183
Geisbert T, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Medicine. 2005;2(6):537-545. https://doi.org/10.1371/journal.pmed.0020183
Geisbert, Thomas ; Jones, Steven ; Fritz, Elizabeth A. ; Shurtleff, Amy C. ; Geisbert, Joan B. ; Liebscher, Ryan ; Grolla, Allen ; Ströher, Ute ; Fernando, Lisa ; Daddario, Kathleen M. ; Guttieri, Mary C. ; Mothé, Bianca R. ; Larsen, Tom ; Hensley, Lisa E. ; Jahrling, Peter B. ; Feldmann, Heinz. / Development of a new vaccine for the prevention of Lassa fever. In: PLoS Medicine. 2005 ; Vol. 2, No. 6. pp. 537-545.
@article{732bbff81f6948e6a343af230d55abfb,
title = "Development of a new vaccine for the prevention of Lassa fever",
abstract = "Background: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. Methods and Findings: We developed a replication-competent vaccine against Lassa virus based on attenuated recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single intramuscular vaccination of the Lassa vaccine elicited a protective immune response in nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected in the monkeys, and none of the animals developed fever or other symptoms of illness associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical disease. In contrast, the two control animals developed severe symptoms including rashes, facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection. Conclusion: Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease.",
author = "Thomas Geisbert and Steven Jones and Fritz, {Elizabeth A.} and Shurtleff, {Amy C.} and Geisbert, {Joan B.} and Ryan Liebscher and Allen Grolla and Ute Str{\"o}her and Lisa Fernando and Daddario, {Kathleen M.} and Guttieri, {Mary C.} and Moth{\'e}, {Bianca R.} and Tom Larsen and Hensley, {Lisa E.} and Jahrling, {Peter B.} and Heinz Feldmann",
year = "2005",
doi = "10.1371/journal.pmed.0020183",
language = "English (US)",
volume = "2",
pages = "537--545",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Development of a new vaccine for the prevention of Lassa fever

AU - Geisbert, Thomas

AU - Jones, Steven

AU - Fritz, Elizabeth A.

AU - Shurtleff, Amy C.

AU - Geisbert, Joan B.

AU - Liebscher, Ryan

AU - Grolla, Allen

AU - Ströher, Ute

AU - Fernando, Lisa

AU - Daddario, Kathleen M.

AU - Guttieri, Mary C.

AU - Mothé, Bianca R.

AU - Larsen, Tom

AU - Hensley, Lisa E.

AU - Jahrling, Peter B.

AU - Feldmann, Heinz

PY - 2005

Y1 - 2005

N2 - Background: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. Methods and Findings: We developed a replication-competent vaccine against Lassa virus based on attenuated recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single intramuscular vaccination of the Lassa vaccine elicited a protective immune response in nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected in the monkeys, and none of the animals developed fever or other symptoms of illness associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical disease. In contrast, the two control animals developed severe symptoms including rashes, facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection. Conclusion: Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease.

AB - Background: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. Methods and Findings: We developed a replication-competent vaccine against Lassa virus based on attenuated recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single intramuscular vaccination of the Lassa vaccine elicited a protective immune response in nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected in the monkeys, and none of the animals developed fever or other symptoms of illness associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical disease. In contrast, the two control animals developed severe symptoms including rashes, facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection. Conclusion: Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease.

UR - http://www.scopus.com/inward/record.url?scp=22144448589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144448589&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.0020183

DO - 10.1371/journal.pmed.0020183

M3 - Article

C2 - 15971954

AN - SCOPUS:22144448589

VL - 2

SP - 537

EP - 545

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 6

ER -